Olga Krökki1, Risto Bloigu2, Hanna Ansakorpi1, Mauri Reunanen1, Anne M Remes3. 1. Institute of Clinical Medicine, Neurology, University of Oulu, Oulu, Finland. 2. Medical Informatics Group, University of Oulu, Oulu, Finland. 3. Institute of Clinical Medicine, Neurology, University of Eastern Finland, Finland; Department of Neurology, Kuopio University Hospital, Kuopio, Finland. Electronic address: anne.remes@uef.fi.
Abstract
OBJECTIVE: There is increasing interest in the survival of multiple sclerosis (MS). MS itself may decrease life expectancy; however, several other comorbid diseases may also influence survival. We aimed to evaluate frequency of other neurological conditions and survival in the population-based Finnish Northern Ostrobothnia MS cohort. METHODS: The frequencies of neurological comorbid diseases and their associations with gender, clinical course, disability level (EDSS) and duration of MS were evaluated in population based cohort of 491 patients with clinically definite MS that was diagnosed between 1990 and 2010. The survival rate of the patients was also analysed. RESULTS: One or more neurological comorbid disease was present in 17.1% of patients (n=84). The prevalence of epilepsy in MS patients was 4.7%, which is greater than that in the general population. Migraine was significantly more common in women with a benign MS course when compared to other types of MS (p=0.046). A significant association between peripheral nervous system disorders and primary progressive MS was found (p=0.027). The 21-year survival rate from time of diagnosis was 90.5%. Stroke decreased the 21-year survival rate of the patients (p=0.003). An association between stroke prevalence and the duration of MS disease was also detected (p=0.023). CONCLUSIONS: This is the first report of multifaceted neurological comorbidities in MS patients. Neurological comorbidity is rather common in MS. However, only the prevalence of epilepsy was increased in MS patients compared to the general population. An association between peripheral nervous system disorders and primary progressive MS was also found. The 21-year survival rate was greater in the present population based cohort compared in other studies, but stroke seems to decrease the survival rate in MS patients.
OBJECTIVE: There is increasing interest in the survival of multiple sclerosis (MS). MS itself may decrease life expectancy; however, several other comorbid diseases may also influence survival. We aimed to evaluate frequency of other neurological conditions and survival in the population-based Finnish Northern Ostrobothnia MS cohort. METHODS: The frequencies of neurological comorbid diseases and their associations with gender, clinical course, disability level (EDSS) and duration of MS were evaluated in population based cohort of 491 patients with clinically definite MS that was diagnosed between 1990 and 2010. The survival rate of the patients was also analysed. RESULTS: One or more neurological comorbid disease was present in 17.1% of patients (n=84). The prevalence of epilepsy in MS patients was 4.7%, which is greater than that in the general population. Migraine was significantly more common in women with a benign MS course when compared to other types of MS (p=0.046). A significant association between peripheral nervous system disorders and primary progressive MS was found (p=0.027). The 21-year survival rate from time of diagnosis was 90.5%. Stroke decreased the 21-year survival rate of the patients (p=0.003). An association between stroke prevalence and the duration of MS disease was also detected (p=0.023). CONCLUSIONS: This is the first report of multifaceted neurological comorbidities in MS patients. Neurological comorbidity is rather common in MS. However, only the prevalence of epilepsy was increased in MS patients compared to the general population. An association between peripheral nervous system disorders and primary progressive MS was also found. The 21-year survival rate was greater in the present population based cohort compared in other studies, but stroke seems to decrease the survival rate in MS patients.
Authors: Kirsten M Fiest; John D Fisk; Scott B Patten; Helen Tremlett; Christina Wolfson; Sharon Warren; Kyla A McKay; Lindsay I Berrigan; Ruth Ann Marrie Journal: Int J MS Care Date: 2016 Mar-Apr
Authors: Ruth Ann Marrie; Nadia Reider; Jeffrey Cohen; Maria Trojano; Per Soelberg Sorensen; Gary Cutter; Stephen Reingold; Olaf Stuve Journal: Mult Scler Date: 2014-12-22 Impact factor: 6.312
Authors: Ruth Ann Marrie; Nadia Reider; Jeffrey Cohen; Olaf Stuve; Maria Trojano; Gary Cutter; Stephen Reingold; Per Soelberg Sorensen Journal: Mult Scler Date: 2014-12-22 Impact factor: 6.312
Authors: Ruth Ann Marrie; Lawrence Elliott; James Marriott; Michael Cossoy; James Blanchard; Stella Leung; Nancy Yu Journal: Neurology Date: 2015-05-27 Impact factor: 9.910